(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 5.18% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Cytek Biosciences's revenue in 2025 is $196,828,000.On average, 7 Wall Street analysts forecast CTKB's revenue for 2025 to be $25,604,932,208, with the lowest CTKB revenue forecast at $24,560,276,546, and the highest CTKB revenue forecast at $26,409,201,988. On average, 7 Wall Street analysts forecast CTKB's revenue for 2026 to be $27,044,690,193, with the lowest CTKB revenue forecast at $25,474,510,081, and the highest CTKB revenue forecast at $28,438,416,840.
In 2027, CTKB is forecast to generate $29,440,877,108 in revenue, with the lowest revenue forecast at $26,904,038,880 and the highest revenue forecast at $31,011,057,220.